These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24029707)

  • 21. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
    Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
    Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
    Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
    J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.
    Kadivar M; Boozari B
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):191-5. PubMed ID: 22914608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
    J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
    [No Abstract]   [Full Text] [Related]  

  • 35. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
    Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
    Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
    Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Large cell carcinoma, lymphoepithelioma-like carcinoma, NUT carcinoma].
    Copin MC
    Ann Pathol; 2016 Jan; 36(1):24-33. PubMed ID: 26739900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.